Clinical TrialJun 8, 2026, 07:01 AM
Mineralys to Present New Lorundrostat Data at ENDO 2026
AI Summary
Mineralys Therapeutics announced that new data from a post hoc analysis of circulating proteomic data from its Launch-HTN and Advance-HTN trials will be featured in a late-breaking poster presentation at ENDO 2026. The data will highlight how lorundrostat modulates heart failure risk biomarkers in participants with uncontrolled hypertension. The presentation is scheduled for Sunday, June 14, 2026, in Chicago.
Key Highlights
- Mineralys to present new post hoc analysis data from Launch-HTN and Advance-HTN trials.
- Data focuses on lorundrostat's modulation of heart failure risk biomarkers.
- Presentation at ENDO 2026, the Endocrine Society's annual meeting, June 13-16.
- Abstract title: "Lorundrostat Modulates Heart Failure Risk Biomarkers in Participants with Uncontrolled Hypertension (SUN-257)".
- Presenter: Kushan Gunawardhana, Mineralys Therapeutics.
- Session on Sunday, June 14, from 9:00 AM - 4:00 PM CT.
- Lorundrostat is an investigational, highly selective aldosterone synthase inhibitor for hypertension.
Price Impact
More from MLYS